Lung cancer test kit GenesWell™ddEGFR
for genesFFPE tissues

lung cancer test kit
lung cancer test kit
lung cancer test kit
Add to favorites
Compare this product

Characteristics

Applications
for lung cancer
Tested parameter
for genes
Sample type
FFPE tissues

Description

"Selection of Patients Who Need Targeted Anti-Cancer Therapy" - Identification of NSCLC (Non-small Cell Lung Cancer) patients for EGFR Tyrosine Kinase Inhibitors (TKIs) treatment - Companion diagnostic test with Tarceva® (Erlotinib) and Tagrisso® (Osimertinib) GenesWell™ddEGFR Mutation Test is a test for the presence of mutations in exons 18, 19, 20, and 21 of the EGFR, which is a biomarker of lung cancer. It can provide a basis for judging the effectiveness of chemotherapy by selecting patients in whom the targeted drug is effective after surgery. GenesWell™ddEGFR Mutation Test can diagnose 46 kinds of mutation part present in the exon (3 on exon 18, 30 on exon 19, 10 on exon 20, 3 on exon 21) among EGFR gene. The panel includes the T790M mutation and C797S mutations, associated with second- and third-generation drug responses, respectively. This diagnoses more mutations and provide doctors and patients with more accurate data than other products in the market.

VIDEO

Catalogs

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.